Research programme: anticancer phospholipid drug conjugates - Cellectar Biosciences

Alternative Names: CLR 1900; CLR 1900 series

Latest Information Update: 31 Jan 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cellectar Biosciences
Class Antineoplastics; Drug conjugates; Phospholipid ethers; Small molecules
Mechanism of Action Mitosis inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

31 Jan 2023 Preclinical development in Solid tumours is still ongoing in USA (Cellectar pipeline, January 2023)
28 Nov 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA
16 Apr 2021 Phospholipid drug conjugates - Cellectar Biosciences is available for licensing as of 16 Apr 2021. https://www.cellectar.com/about

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com